**A Study to Compare the Efficacy and Safety of Treatments for Follicular Lymphoma** This study evaluates how well a new drug combo, *golcadomide* with *rituximab*, works compared to other treatments chosen by doctors for people with *relapsed/refractory follicular lymphoma* (a type of blood cancer). *Relapsed* means the cancer came back, while *refractory* means the cancer didn't respond to previous treatments. **Key Points:** - **Duration & Visits**: Participants will be involved in this study for an extended period with regular doctor visits and tests. - **Eligibility**: Participants should have had at least one previous treatment line and meet certain health criteria. - **Risks & Benefits**: Participants may experience side effects but could benefit from a potentially effective treatment. Participants must have a confirmed diagnosis of follicular lymphoma and show evidence of the disease through PET scans. They should have tried at least one treatment including an anti-CD20 antibody, like rituximab. People with certain other health conditions may not be eligible. The study aims to provide insights into effective treatments for those who have not responded to previous therapies.